No Data
No Data
Emerging Trends in Oncology: ASCO 2024 Highlights Next-Gen Antibody-Drug Conjugates and More
USA News Group News Commentary – As the 2024 American Society of Clinical Oncology (ASCO) annual meeting approaches, excitement builds over the...
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower
European equities traded in the US as American depositary receipts were moving higher Friday morning, rising 0.63% to 1,424.72 on the S&P Europe Select ADR Index. However, the gain likely won't be eno
Critical Insights From BioNTech Analyst Ratings: What You Need To Know
Across the recent three months, 11 analysts have shared their insights on BioNTech (NASDAQ:BNTX), expressing a variety of opinions spanning from bullish to bearish.In the table below, you'll find a su
Deutsche Numis Maintains BioNTech(BNTX.US) With Hold Rating, Maintains Target Price $95
Deutsche Numis analyst Emmanuel Papadakis maintains $BioNTech(BNTX.US)$ with a hold rating, and maintains the target price at $95.According to TipRanks data, the analyst has a success rate of 58.8% an
BofA Securities Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $146
BofA Securities analyst Tazeen Ahmad maintains $BioNTech(BNTX.US)$ with a buy rating, and maintains the target price at $146.According to TipRanks data, the analyst has a success rate of 46.5% and a t
H.C. Wainwright Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $113
H.C. Wainwright analyst Robert Burns maintains $BioNTech(BNTX.US)$ with a buy rating, and maintains the target price at $113.According to TipRanks data, the analyst has a success rate of 23.4% and a t